At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 8 enrolled
Drug / intervention
Belumosudildrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a, Open-label Study to Evaluate the Safety and Tolerability of KD025 [Belumosudil] Treatment in Subjects With Moderately Severe Psoriasis Vulgaris Who Have Failed First-line Therapy
In Brief
A Phase 2 clinical trial evaluating Belumosudil for Psoriasis Vulgaris. Completed, enrolled 8 participants across 1 site.
Detailed Summary
The primary objective is to assess the safety and tolerability of 200 mg of belumosudil administered orally once daily for 28 days.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis Vulgaris
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartApr 2014
First PostedApr 2014
Primary CompletionSep 2014
TodayJul 2026
First PostedApr 8, 2014
Enrollment StartApr 1, 2014
Primary CompletionSep 1, 2014
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 12.2 years ago
Interventions
Belumosudildrug